Cabaletta Bio Inc. shares /zigman2/quotes/214676209/composite CABA -2.11% slid 18% in their trading debut Friday, after underwriters priced the deal at $11, a full $3 below the $14 to $16 price range. The stock was last down $1.99 at $9.01. The clinical-stage biotech's stock is trading on Nasdaq, under the ticker symbol "CABA." Morgan Stanley, Cowen and Evercore were underwriters on the deal. "We are a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases," the company said in its prospectus.